Davide Busato

6PUBLICATIONS
11CO-AUTHORS
Pacific Peoples diet and nutritionNeural engineeringCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 25, 2026
PLGA/PVA nanoparticles to deliver a protein-based cancer vaccine targeting GPC1 for the treatment of pancreatic ductal adenocarcinoma.

|Apr 26, 2025
Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer.

Idris Vruzhaj, Marta Gambirasi, Davide Busato

|Jan 15, 2025
Idarubicin-loaded chitosan nanobubbles to improve survival and decrease drug side effects in hepatocellular carcinoma.

Monica Mossenta, Monica Argenziano, Sara Capolla

|Sep 23, 2022
The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma.

Davide Busato, Monica Mossenta, Michele Dal Bo

|Sep 09, 2022
Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies.

Monica Mossenta, Davide Busato, Michele Dal Bo

|Jan 27, 2021
A Novel Epigenetic Machine Learning Model to Define Risk of Progression for Hepatocellular Carcinoma Patients.

Luca Bedon, Michele Dal Bo, Monica Mossenta

Pageof 1

Frequent Collaborators

5 joint publications

Michele Dal Bo

5 joint publications

Giuseppe Toffoli

3 joint publications

Monica Mossenta

3 joint publications

Paolo Macor